In a report released today, Marie Thibault from BTIG maintained a Buy rating on Insulet, with a price target of $370.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Marie Thibault has given her Buy rating due to a combination of factors that highlight Insulet’s promising growth trajectory and strategic initiatives. Insulet is expected to provide long-term financial targets and growth expectations during its upcoming Investor Day, with projections indicating a significant revenue increase by 2027. The company’s commitment to balancing reinvestment with margin expansion is also a key consideration, as they aim for annual operating margin improvements.
Additionally, Insulet’s strategic priorities, such as accelerating innovation and expanding market presence, are crucial in driving future growth. The company has made notable progress in increasing customer starts among Type 1 and Type 2 diabetes patients, with a particular focus on the relatively untapped Type 2 market. These efforts, combined with Insulet’s plans to enhance global operational scale, support Thibault’s positive outlook and Buy rating for the stock.
According to TipRanks, Thibault is an analyst with an average return of -5.8% and a 37.75% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Boston Scientific, Accuray, and Irhythm Technologies.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $360.00 price target.